By vgreene, 29 April, 2020 Study considerations not peer reviewed active control more severe critical pts in FPV group pts received other antivirals and traditional Chinese medicine limited observation time frame
By vgreene, 29 April, 2020 No significant difference in primary endpoint of clinical recovery rate on day 7 (61% FPV, 51% umifenovir); quicker defervescence and sx relief w/ FPV in pts w/ moderate dz; no difference in rate of auxiliary O2 tx or noninvasive mechanical ventilation; h
By vgreene, 29 April, 2020 Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring; pre-print medRxiv article
By vgreene, 29 April, 2020 Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis; pre-print medRxiv article
By vgreene, 28 April, 2020 Consider COVID-19 test, esp in pts w/ fever, cough/ dyspnea,1 factoring test availability; consider flu,1,4 other co-infections.2 Absence of imaging shouldn’t delay empiric tx3
By vgreene, 28 April, 2020 Priority: pts w/ COVID-19 sx (incl sore throat, chills, diarrhea, new anosmia, chest pain, etc.); pts w/o sx prioritized by clinicians/health dept for any reason (eg, surveillance, state/local screening programs, etc)1